Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes in a Brazilian population

References

• Alves-Silva J, da Silva Santos M, Guimaraes PE, Ferreira AC, Bandelt HJ, Pena SD, Prado VF. (2000). The ancestry of Brazilian mtDNA lineages. Am J Hum Genet 67:444–461.
   PubMed Web of Science ®Google Scholar
• Arruda VR, Grignolli CE, Goncalves MS, Soares MC, Menezes R, Saad ST, Costa FF. (1998). Prevalence of homozygosity for the deleted alleles of glutathione S-transferase l (GSTM1) and u (GSTT1) among distinct ethnic groups from Brazil: relevance to environmental carcinogenesis? Clin Genet 54:210–214.
   PubMed Web of Science ®Google Scholar
• Aydin M, Hatirnaz O, Erensoy N, Ozbek U. (2005). CYP2D6 and CYP1A1 mutations in the Turkish population. Cell Biochem Funct 2005;23:133–135.
   PubMed Web of Science ®Google Scholar
• Baquet CR, Horm JW, Gibbs T, Greenwald P. (1991). Socioeconomic factors and cancer incidence among blacks and whites. J Natl Cancer Inst 83:551–557.
   PubMed Web of Science ®Google Scholar
• Bradford LA. (2002). CYP2D6 allele frequency in European Caucasians, Asians, African and their descendants. Pharmacogenetics 3:229–243.
   Google Scholar
• Carvalho-Silva DR, Santos FR, Rocha J, Pena SD. (2001). The phylogeography of Brazilian Y-chromosome lineages. Am J Hum Genet 68:281–286.
   PubMed Web of Science ®Google Scholar
• d’Errico A, Taioli E, Chen X et al. (1996). Genetic metabolic polymorphisms and the risk of cancer. A review of the literature. Biomarkers 1:149–173.
   PubMed Web of Science ®Google Scholar
• Fretland AJ, Omiecinski CJ. (2000). Epoxide hydrolases: biochemistry and molecular biology. Chem Biol Interact 129:41–59.
   PubMed Web of Science ®Google Scholar
• Garte S. (1998). The role of ethnicity in cancer susceptibility gene polymorphisms: the example of CYP1A1. Carcinogenesis 19:1329–1332.
   PubMed Web of Science ®Google Scholar
• Gough AC, Miles JS, Spurr NK, Moss JE, Gaedigk A, Eichelbaum M, Wolf CR. (1990). Identification of the primary gene defect at the cytochrome P450 CYP2D locus. Nature 347:773–776.
   PubMed Web of Science ®Google Scholar
• Halling J, Petersen MS, Damkier P, Nielsen F, Grandjean P, Weihe P, Lundgren S, Lundblad MS, Brøsen K. (2005). Polymorphism of CYP2D6, CYP2C19, CYP2C9 and CYP2C8 in the Faroese population. Eur J Clin Pharmacol 61:491–497.
   PubMed Web of Science ®Google Scholar
• Hassett C, Lin J, Carty CL, Laurenzana EM, Omiecinski CJ. (1997). Human hepatic microsomal epoxide hydrolase: comparative analysis of polymorphic expression. Arch Biochem Biophys 15:275–283.
   Google Scholar
• Hori H, Ohmori O, Matsumoto C, Shinkai T, Nakamura J. (2003). NAD(P)H: quinone oxidoreductase (NQO1) polymorphism and schizophrenia. Psychiatry Res 118:235–239.
   PubMed Web of Science ®Google Scholar
• Huang WY, Chatterjee N, Chanock S, Dean M, Yeager M, Schoen RE, Hou LF, Berndt SI, Yadavalli S, Johnson CC, Hayes RB. (2005). Microsomal epoxide hydrolase polymorphisms and risk for advanced colorectal adenoma. Cancer Epidemiol Biomarkers Prev 14:152–157.
   PubMed Web of Science ®Google Scholar
• Ingelman-Sundberg M. (2001). Genetic susceptibility to adverse effects of drugs and environmental toxicants. The role of the CYP family of enzymes. Mutat Res 482:11–19.
   PubMed Web of Science ®Google Scholar
• Kelsey KT, Ross D, Traver RD et al. (1997). Ethnic variation in the prevalence of a common NAD(P)H quinone oxidoreductase polymorphism and its implications for anti-cancer chemotherapy. Br J Cancer 76:852–854.
   PubMed Web of Science ®Google Scholar
• Kiffmeyer WR, Langer E, Davies SM, Envall J, Robison LL, Ross JA. (2004). Genetics polymorphisms in the Hmong population. Cancer 100:411–417.
   PubMed Web of Science ®Google Scholar
• Krajinovic M, Sinnett H, Richer C, Labuda D, Sinnett D. (2002). Role of NQO1, MPO and CYP2E1 genetic polymorphisms in the susceptibility to childhood acute lymphoblastic leukemia. Int J Cancer 97:230–236.
   PubMed Web of Science ®Google Scholar
• Lancaster JM, Brownlee HA, Bell DA, Futreal PA, Marks JR, Berchuck A, Wiseman RW, Taylor JA. (1996). Microsomal epoxide hydrolase polymorphism as a risk factor for ovarian cancer. Mol Carcinog 17:160–162.
   PubMed Web of Science ®Google Scholar
• Leathart JBS, London SJ, Steward A, Adams JD, Idle JR, Daly AK. (1998). CYP2D6 phenotype-genotype relationships in African-Americans and Caucasians in Los Angeles. Pharmacogenetics 8:529–514.
   PubMedGoogle Scholar
• Lemos MC, Cabrita FJ, Silva HA, Vivan M, Placido F, Regateiro FJ. (1999). Genetic polymorphism of CYP2D6, GSTM1 and NAT2 and susceptibility to haematological neoplasias. Carcinogenesis 20:1225–1229.
   PubMed Web of Science ®Google Scholar
• Meyer UA, Zanger UM. (1997). Molecular mechanism of genetic polymorphism of drug metabolism. Ann Rev Pharmacol Toxicol 37:269–296.
   PubMed Web of Science ®Google Scholar
• Mitrou PN, Watson MA, Loktionov AS, Cardwell C, Gunter MJ, Atkin WS, Macklin CP, Cecil T, Bishop DT, Primrose J, Bingham SA. (2007). Role of NQO1C609T and EPHX1 gene polymorphisms in the association of smoking and alcohol with sporadic distal colorectal adenomas: results from the UKFSS Study. Carcinogenesis 28:875–882.
   PubMed Web of Science ®Google Scholar
• Park JY, Schantz SP, Lazarus P. (2003). Epoxide hydrolase genotype and orolaryngeal cancer risk: interaction with GSTM1 genotype. Oral Oncol 39:483–490.
   PubMed Web of Science ®Google Scholar
• Raucy JL, Allen SW. (2001). Recent advances in P450 research. Pharmacogenomics J 1:178–186.
   PubMedGoogle Scholar
• Sachse C, Brockmoller J, Bauer S, Roots I. (1997). Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60:284–295.
   PubMed Web of Science ®Google Scholar
• Smith CA, Harrison DJ. (1997). Association between polymorphism in gene for microsomal epoxide hydrolase and susceptibility to emphysema. Lancet 350:630–633.
   PubMed Web of Science ®Google Scholar
• Smith CA, Gough AC, Leigh PN, Summers BA, Harding AE, Maraganore DM, Sturman SG, Schapira AH, Williams AC. (1992). Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson’s disease. Lancet 339:1375–1377.
   PubMed Web of Science ®Google Scholar
• Steijins L, Van Der Weide J. (1998). Ultrarapid drug metabolism: PCR based detection of CYP2D6 gene duplication. Clin Chem 44:914–917.
   PubMed Web of Science ®Google Scholar
• Taningher M, Malacarne D, Izzotti A, Ugolini D, Parodi S. (1999). Drug metabolism polymorphisms as modulators of cancer susceptibility. Mutat Res 436:227–261.
   PubMed Web of Science ®Google Scholar
• Trapido EJ, Chen F, Davis K, Lewis N, MacKinnon JA. (1994). Cancer among Hispanic males in south Florida. Nine years of incidence data. Arch Intern Med 154:177–185.
   PubMedGoogle Scholar
• Tranah GJ, Giovannucci E, Ma J, Fuchs C, Hankinson SE, Hunter DJ. (2004). Epoxide hydrolase polymorphisms, sigarette smoking and risk of colorectal adenoma in the Nurses’ Health Study and the Health Professionals Follow-up Study. Carcinogenesis 25:1211–1218.
   PubMed Web of Science ®Google Scholar
• Traver RD, Siegel D, Beall HD, Phillips RM, Gibson NW, Franklin WA, Ross D. (1997). Characterization of a polymorphism in NAD(P) H: quinone oxidoreductase (DT-di aphorase). Br J Cancer 75:69–75.
   PubMed Web of Science ®Google Scholar
• Van der Logt EM, Bergevoet SM, Roelofs HM, Te Morsche RH, Dijk Y, Wobbes T, Nagengast FM, Peters WH. (2006). Role of epoxide hydrolase, NAD(P)H:quinone oxidoreductase, cytochrome P450 2E1 or alcohol dehydrogenase genotypes in susceptibility to colorectal cancer. Mutat Res 593:39–49.
   PubMed Web of Science ®Google Scholar
• Vodicka P, Soucek P, Tates AD, Dusinska M, Sarmanova J, Zamecnikova M, Vodickova L, Koskinen M, de Zwart FA, Natarajan AT, Hemminki K. (2001). Association between genetic polymorphisms and biomarkers in styrene-exposed workers. Mutat Res 482:89–103.
   PubMed Web of Science ®Google Scholar
• Wang LD, Zheng S, Liu B, Zhou JX, Li YJ, Li JX. (2003). CYP1A1, gsts and meh polymorphisms and susceptibility to esophageal carcinoma: study of population from a high-incidence area in north China. World J Gastroenterol 9:1394–1397.
   PubMed Web of Science ®Google Scholar
• Wiemels JL, Pagnamenta A, Taylor GM, Eden OB, Alexander FE, Greaves MF. (1999). A lack of a functional NAD(P)H:quinone oxidoreductase allele is selectively associated with pediatric leukemias that have MLL fusions. Cancer Res 59:4095–4099.
   PubMed Web of Science ®Google Scholar
• Yin L, Pu Y, Liu TY, Tung YH, Chen KW, Lin P. (2001). Genetic polymorphisms of NAD(P)H quinone oxidoreductase, CYP1A1 and microsomal epoxide hydrolase and lung cancer risk in Nanjing, China. Lung Cancer 33:133–141.
   PubMed Web of Science ®Google Scholar
• Yoshimura K, Hanaoka T, Ohnami S, Ohnami S, Kohno T, Liu Y, Yoshida T, Sakamoto H, Tsugane S. (2003). Allele frequencies of single nucleotide polymorphisms (SNPs) in 40 candidate genes for gene-environment studies on cancer: data from population-based Japanese random samples. J Hum Genet 48:654–658.
   PubMed Web of Science ®Google Scholar
• Zahm SH, Fraumeni JF Jr. (1995). Racial, ethnic, and gender variations in cancer risk: considerations for future epidemiologic research. Environ Health Perspect 103:283–286.
   PubMed Web of Science ®Google Scholar
• Zidzik J, Slabá E, Joppa P, Kluchová Z, Dorková Z, Skyba P, Habalová V, Salagovic J, Tkácová R. (2008). Glutathione S-transferase and microsomal epoxide hydrolase gene polymorphisms and risk of chronic obstructive pulmonary disease in Slovak population. Croat Med J 49:182–191.
   PubMed Web of Science ®Google Scholar